FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to a double GIP/GLP-1 receptor agonist, which is a compound of formula I or a pharmaceutically acceptable salt thereof, where R1 is selected from a group consisting of -C(=O)(OZ1) and -P(=O)(X)(Y); R2 is selected from a group consisting of -C(=O)(OZ2) and -P(=O)(X)(Y); X and Y each represent -OR4; where R4, Z1 and Z2 are defined in the claims. Also disclosed is a pharmaceutical composition containing a compound of formula I, and a method of treating metabolic disorders and fatty liver diseases.
EFFECT: compositions and methods for treating metabolic and hepatic disorders are disclosed.
36 cl, 6 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHOSPHORUS(N)AMIDATEACETAL AND PHOSPH(OH)ATACETAL COMPOUNDS | 2019 |
|
RU2796403C2 |
| BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USE | 2017 |
|
RU2773346C2 |
| SELECTIVE ESTROGEN RECEPTOR INHIBITORS AND USE THEREOF | 2017 |
|
RU2734501C2 |
| DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | 2015 |
|
RU2673944C2 |
| CYANOTHIENOTRIAZOLODIAZEPINES AND METHODS FOR THEIR USE | 2016 |
|
RU2750164C2 |
| NEUROACTIVE STEROIDS SUBSTITUTED AT POSITION 10 WITH A CYCLIC GROUP FOR USE IN THE TREATMENT OF CNS DISORDERS | 2019 |
|
RU2796006C2 |
| DERIVATIVES OF PYRAZIOLE WITH CONDENSED CYCLE | 2002 |
|
RU2318822C2 |
| BIVALENT BROMODOMAIN INHIBITORS AND ROUTES OF USE THEREOF | 2016 |
|
RU2742035C2 |
| NEUROACTIVE COMPOUNDS AND THEIR APPLICATION METHODS | 2015 |
|
RU2764702C2 |
| BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS FOR USE THEREOF | 2016 |
|
RU2712099C2 |
